- Home
- ALH vs VKTX Comparison
ALH vs VKTX Comparison
Compare ALH & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALH | VKTX |
|---|---|---|
| Founded | 1908 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.8B |
| IPO Year | 2025 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ALH | VKTX |
|---|---|---|
| Price | $21.39 | $32.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | $31.38 | ★ $87.07 |
| AVG Volume (30 Days) | 1.4M | ★ 2.6M |
| Earning Date | 02-23-2026 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.36 | N/A |
| EPS | ★ 0.67 | N/A |
| Revenue | ★ $1,669,499,000.00 | N/A |
| Revenue This Year | $13.30 | N/A |
| Revenue Next Year | $6.20 | N/A |
| P/E Ratio | $32.47 | ★ N/A |
| Revenue Growth | ★ 22.29 | N/A |
| 52 Week Low | $20.10 | $18.92 |
| 52 Week High | $27.48 | $43.15 |
Technical Indicators
Market Signals| Indicator | ALH | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 37.14 |
| Support Level | N/A | $31.59 |
| Resistance Level | N/A | $33.35 |
| Average True Range (ATR) | 0.00 | 1.49 |
| MACD | 0.00 | -0.47 |
| Stochastic Oscillator | 0.00 | 9.57 |
Price Performance
Historical ComparisonAbout ALH Alliance Laundry Holdings Inc.
Alliance Laundry Holdings Inc is designer and manufacturer of commercial laundry systems, serving diverse international markets. The company offers premium, durable laundry equipment under brands like Speed Queen, UniMac, Huebsch, Primus, IPSO, and others. It serves commercial laundry needs across healthcare, hotels, laundromats, and residential markets.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.